ALLYSON FEIST: Open Payments
NPI 1376192138 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,617 in 233 payments from 15 companies in 2025. Trend: 2023 $3,687 · 2024 $3,590 · 2025 $3,617
Food & beverage: $3,617
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 25 | $491 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $403 |
| Otsuka America Pharmaceutical, Inc. | 52 | $347 |
| Axsome Therapeutics, Inc. | 17 | $316 |
| Teva Pharmaceuticals USA, Inc. | 13 | $293 |
| E.R. Squibb & Sons, L.L.C. | 19 | $286 |
| ABBVIE INC. | 27 | $275 |
| Janssen Pharmaceuticals, Inc | 13 | $268 |
| Vanda Pharmaceuticals Inc. | 15 | $210 |
| Noven Therapeutics, LLC | 11 | $203 |
Products named: INGREZZA, REXULTI, CAPLYTA, COBENFY, VRAYLAR, Auvelity, SPRAVATO, FANAPT.
Industry payments across TX — which companies pay providers there.
